Table 5.

Univariate Cox regression analysis of bridging therapy use with progression-free survival

Variable	HR (95% CI)	SE	P value
Age	1.00 (0.98 to 1.01)	0.01	0.556
Female sex	0.87 (0.58 to 1.29)	0.17	0.475
Married/with a life partner	0.80 (0.53 to 1.20)	0.17	0.276
Charlson Comorbidity Index score	1.04 (0.78 to 1.37)	0.15	0.800
Double hit lymphoma diagnosis	1.39 (0.87 to 2.22)	0.33	0.171
Number of prior therapies	1.05 (0.94 to 1.18)	0.06	0.397
Prior autologous stem cell transplant	0.53 (0.32 to 0.88)	0.14	0.013
Months from relapse to CAR T-cell infusion	0.86 (0.68 to 1.07)	0.10	0.180
Vein-to-vein time (months)	0.85 (0.54 to 1.33)	0.19	0.471
ECOG performance status	1.23 (0.98 to 1.54)	0.14	0.078
LDH >500 (U/L, prior to CAR T-cell infusion)	2.04 (1.28 to 3.24)	0.48	0.003
CRP >30 (mg/L, prior to CAR T-cell infusion)	2.10 (1.43 to 3.08)	0.41	<0.001
Ferritin ≥411 (µg/L, prior to CAR T-cell infusion)	1.10 (0.73 to 1.68)	0.24	0.645
Platelet count <100 K/µL	1.31 (0.84 to 2.03)	0.29	0.228
Bridging therapy use	1.50 (1.02 to 2.20)	0.29	0.041
CD28 co-stimulatory domain CAR T-cell product	0.64 (0.39 to 1.04)	0.16	0.072
Dexamethasone dose (dg) from days 0–31	1.08 (1.00 to 1.18)	0.05	0.081
Receipt of tocilizumab	0.63 (0.43 to 0.92)	0.12	0.018

CAR, chimeric antigen receptor; CRP, C-reactive protein; dg, decigram; ECOG, Eastern Cooperative Oncology Group; LDH, lactate dehydrogenase.